{"id":5886,"date":"2024-12-02T15:23:45","date_gmt":"2024-12-02T21:23:45","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5886"},"modified":"2025-06-27T08:31:42","modified_gmt":"2025-06-27T13:31:42","slug":"nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","title":{"rendered":"El programa de retinosis pigmentaria de Nanoscope se presentar\u00e1 en el Congreso FLORetina 2024"},"content":{"rendered":"
\n
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS, 2 de diciembre de 2024 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda en fase cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina (ERH) y atrofia geogr\u00e1fica (AG) secundaria a la degeneraci\u00f3n macular, anunci\u00f3 hoy que Jordi Mon\u00e9s ofrecer\u00e1 una presentaci\u00f3n de datos cl\u00ednicos de Nanoscope en la conferencia anual\u00a0Conferencia FLORetina\u00a0<\/a>que tendr\u00e1 lugar el 5 de diciembreth<\/sup>-8th<\/sup>\u00a0en la Fortezza da Basso en Florencia, Italia. Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

T\u00edtulo:<\/strong>\u00a0Eficacia y seguridad longitudinales de la terapia optogen\u00e9tica MCO-010 para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a retinitis pigmentosa: resultados de 126 semanas de un estudio de seguimiento a largo plazo (REMAIN)<\/a><\/p>\n

T\u00edtulo de la sesi\u00f3n<\/strong>:Retina Futura, Sesi\u00f3n 1
\nFecha de la sesi\u00f3n:\u00a0<\/strong>6 de diciembreth<\/sup>, 2024
\nTiempo de sesi\u00f3n:\u00a0<\/strong>12:18 pm CEST
\nUbicaci\u00f3n:<\/strong> Sala San Giovanni, Fortezza da Basso, Florencia
\nPresentador:\u00a0<\/strong>Jordi Mon\u00e9s, MD, PhD, Director del Institut de la M\u00e0cula y Barcelona Macula Foundation (Espa\u00f1a)<\/p>\n

Adem\u00e1s de las mejoras estad\u00edsticamente significativas observadas en la agudeza visual mejor corregida (MAVC) en pacientes con retinosis pigmentaria (RP) tratados con Opsina MultiCaracter\u00edstica (MCO-010) en el ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE, el Dr. Mon\u00e9s presentar\u00e1 la eficacia y seguridad duraderas hasta 126 semanas observadas en el estudio de seguimiento a largo plazo REMAIN.<\/p>\n

Acerca de Nanoscope Therapeutics, Inc.
\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para GA.<\/p>\n

Contacto de inversores:<\/strong>
\nSocios Argot
\n212-600-1902
\nPR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS, Dec. 2, 2024 \u00a0\u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) secondary to macular degeneration, today announced that Jordi Mon\u00e9s will provide a presentation of Nanoscope clinical data at the annual\u00a0FLORetina conference\u00a0taking place on\u00a0December 5th-8th\u00a0at the Fortezza da Basso in\u00a0Florence Italy. Details […]<\/p>\n","protected":false},"author":6,"featured_media":5889,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T21:23:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:31:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress\",\"datePublished\":\"2024-12-02T21:23:45+00:00\",\"dateModified\":\"2025-06-27T13:31:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\"},\"wordCount\":319,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\",\"name\":\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"datePublished\":\"2024-12-02T21:23:45+00:00\",\"dateModified\":\"2025-06-27T13:31:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El programa de Nanoscope para la retinosis pigmentaria se presentar\u00e1 en el Congreso FLORetina 2024 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-12-02T21:23:45+00:00","article_modified_time":"2025-06-27T13:31:42+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress","datePublished":"2024-12-02T21:23:45+00:00","dateModified":"2025-06-27T13:31:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/"},"wordCount":319,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","url":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","name":"El programa de Nanoscope para la retinosis pigmentaria se presentar\u00e1 en el Congreso FLORetina 2024 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","datePublished":"2024-12-02T21:23:45+00:00","dateModified":"2025-06-27T13:31:42+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5886"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5886\/revisions"}],"predecessor-version":[{"id":9009,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5886\/revisions\/9009"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5889"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}